Trial Breakthrough: Social media has been abuzz with analysis of AbCellera Biologics' recent Phase 2 results for ABCL635, which many describe as a pivotal de-risking moment for its internal pipeline. Participants note the data's alignment with the company's target product profile, sparking broader conversations about its potential to evolve beyond platform licensing.
Capital and Insider Moves: The week's developments also include a $200 million oversubscribed offering and reported open-market purchases by the CFO and a director, prompting discussions on leadership alignment with growth prospects. Observers point to these actions as reinforcing the firm's strategic shift toward becoming a more integrated pharmaceutical entity.
Investor Sentiment: Commentary across social media reflects a positive tone overall, with users highlighting how the combined news flow has elevated perceptions of the company's long-term capabilities in drug development.
Note: This discussion summary was generated from an AI condensation of post data.
AbCellera Biologics Insider Trading Activity
AbCellera Biologics insiders have traded $ABCL stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABCL stock by insiders over the last 6 months:
- HOLDINGS LTD. THERMOPYLAE has made 2 purchases buying 215,457 shares for an estimated $711,004 and 0 sales.
- ANDREW BOOTH (Chief Financial Officer) has made 2 purchases buying 79,800 shares for an estimated $529,596 and 0 sales.
- MICHAEL R HAYDEN purchased 46,387 shares for an estimated $481,033
- JOHN S. MONTALBANO purchased 20,000 shares for an estimated $95,399
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AbCellera Biologics Hedge Fund Activity
We have seen 82 institutional investors add shares of AbCellera Biologics stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 4,751,080 shares (+81.8%) to their portfolio in Q1 2026, for an estimated $16,581,269
- GOLDMAN SACHS GROUP INC removed 3,516,085 shares (-93.7%) from their portfolio in Q2 2026, for an estimated $27,601,267
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,258,270 shares (-43.0%) from their portfolio in Q2 2026, for an estimated $25,577,419
- JEFFERIES FINANCIAL GROUP INC. added 2,746,200 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,584,238
- BAKER BROS. ADVISORS LP added 2,736,200 shares (+9.0%) to their portfolio in Q2 2026, for an estimated $21,479,170
- ALYESKA INVESTMENT GROUP, L.P. added 2,592,105 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,046,446
- UBS GROUP AG removed 2,338,419 shares (-55.6%) from their portfolio in Q2 2026, for an estimated $18,356,589
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AbCellera Biologics Price Targets
Multiple analysts have issued price targets for $ABCL recently. We have seen 3 analysts offer price targets for $ABCL in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Robert Wasserman from Benchmark set a target price of $11.0 on 07/07/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $7.0 on 05/05/2026
- Debanjana Chatterjee from Jones Trading set a target price of $11.0 on 04/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
